

## Short Biography Nico van Zandwijk

With 40 years of experience in thoracic oncology professor emeritus van Zandwijk is an opinion leader in his own right. He established the Dept. of Thoracic Oncology at the Netherlands Cancer Institute (1985). He was secretary and chair of the EORTC Lung Cancer Cooperative Group (1984-1992), board member of the International Association for the Study of Lung Cancer, co-chair of the World Lung Cancer Conference in 2011. In 2008, he became the inaugural director of the Asbestos Diseases Research Institute (ADRI) in Sydney, was founding member of the Australian Mesothelioma Registry and coordinated the drafting of the Australian Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma (MPM), endorsed by NHMRC (2013). Professor van Zandwijk (co) authored more than 400 peer-reviewed papers and chapters (>19700 citations; h-index 74). His work encompasses translational research and clinical trials with a focus on asbestos-related cancer. The Euroscan chemoprevention study (JNCI 2000) and a phase I trial with a novel gene therapy for MPM (Lancet Oncology, October 2017) are examples of projects lead by him that continue to attract worldwide attention.

Professor van Zandwijk is employed by Sydney Local Health District, associated with Concord Clinical School and honorary staff member of the Dept. of Cell and Molecular Therapies at Royal Prince Alfred Hospital.